Health
Virus drug benefit only marginal: study – Education – Australian Associated Press
Researchers say a new study of Gilead Sciences’ remdesivir raises questions about the efficacy of the drug in the treatment of COVID-19.
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.
The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.
The 600-patient analysis, published on Friday by the Journal of the American Medi…
-
Noosa News13 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General11 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
Noosa News12 hours agoLyka Doggie Date Night at Moonlight Cinema
-
Noosa News12 hours agoQueensland Drug and Alcohol Court provides sentencing options – Proctor